Long-term benefits of single-dose psilocybin in depressed patients with cancer

Abstract

Background: Patients with cancer often struggle with depression, which can negatively impact quality of life as well as be challenging to manage. Methods: A phase 2 trial was conducted that demonstrated safety, feasibility, and efficacy of a single dose of psilocybin combined with psychological support in a community cancer setting in 30 patients with cancer and a major depressive disorder. Here, efficacy outcomes at 2 years’ follow-up are reported. Results: Of 28 patients, 15 (53.6%) demonstrated significant reduction in depression as measured by the Montgomery Asberg Depression Rating Scale (average, –15.0 points from baseline; p